Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Full description

Bibliographic Details
Main Authors: John J. O'Leary, Sharon A. O'Toole, Feras Abu Saadeh, Charles d'Adhemar, Lucy Norris, Ream Langhe, Tom D'Arcy, Noreen Gleeson, Margaret Lawson, Orla Sheils, Martina Ring, Anthony Davies, Cara Martin, Lynda McEvoy, Stephen Finn, Michael Gallagher, Lynne Kelly, Alexandros Laios, Richard Flavin, Bashir M. Mohamed
Format: Article
Language:English
Published: MDPI AG 2013-01-01
Series:International Journal of Molecular Sciences
Subjects:
ovarian
MMP-9/MMP-2 inhibitor
chemoresistance
recurrent
high content screening
Online Access:http://www.mdpi.com/1422-0067/14/1/2085

Internet

http://www.mdpi.com/1422-0067/14/1/2085

Similar Items